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Purpose of the review: This review was conducted to determine the ethical acceptability of prescribing generic
immunosuppressive drugs to renal transplant patients.
Sources of information: The literature search was conducted using Pubmed and Google Scholar.
Findings: The use of generic immunosuppressive drugs (ISDs) in transplantation is a controversial topic. There is a
consensus among transplant societies that clinical data is lacking and that caution should be exercised. The
reluctance to use generic ISDs in organ transplantation is partly related to the fact that most are “critical dose
drugs”, and that either low dosing or overdosing could have serious adverse consequences for both patients and
society (i.e., the loss of scarce organs). In this paper, we examine the various ethical issues involved such as
distributive justice, physician duties, risks versus benefits, conflict of interest, informed consent, and logistical and
economic issues.
Limitations: Our analysis was limited by the paucity of clinical data on generic ISDs and the absence of health
economics studies to quantify the benefits of prescribing generic ISDs.
Implications: Our study led us to conclude that it would be ethical to prescribe generic ISDs provided certain
conditions were met. These include regulatory safeguards to minimize the risks of substitution; education of
patients; and further clinical and health economics studies to better inform clinicians, patients and society of the
risks and costs related to drug substitution.
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But de l’article: Le but de cet article est de questionner s’il est éthique de prescrire des immunosuppresseurs
génériques aux patients transplantés d’un rein.
Sources d’informations: Nous avons effectué une recension des écrits en utilisant Pubmed et Google Scholar.
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Résultats: La prescription d’immunosuppresseurs génériques en transplantation rénale est un sujet controversé. Les
sociétés savantes sont en accord sur le fait qu’il y a un manque de données cliniques et que la prudence est de mise.
Une des explications à cette attitude réfractaire est le fait que les immunosuppresseurs sont considérés comme
des « médicaments à dose critique ». Par conséquent, leur surdosage ou leur sous-dosage peut avoir des conséquences
désastreuses pour le patient et la société (i.e., la perte d’un greffon). Dans cet article, nous examinerons les enjeux
éthiques impliqués dans ce débat tels que la justice distributive, les devoirs des médecins, l′analyse des risques et des
bénéfices, le conflit d’intérêt, le consentement éclairé ainsi que des enjeux logistiques et économiques.
Limites: Les données cliniques existantes sont insuffisantes et limitent notre analyse. De plus, l′absence d’analyse
économique sur l′utilisation d’immunosuppresseurs génériques constitue une autre limite à notre étude.
Implications: Suite à cette analyse, nous pouvons conclure qu’il serait éthique de prescrire des immunosuppresseurs
génériques dans certaines circonstances. Celles-ci incluent la mise en place de mesures qui minimisent les risques de
substitution, l′éducation des patients et la réalisation d’études cliniques et économiques afin de mieux informer les
cliniciens, les patients et la société sur les risques reliés à la prescription de ces médicaments ainsi qu’aux coûts associés.What was known before?
The prescription of generic ISDs is controversial. There
is a concern that the bioequivalence acceptability range
could lead to generic drift.
What this adds
This review enhances existing knowledge with an ana-
lysis of the ethical issues related to the prescription of
generic ISDs.
Why is this review important?
This review explores the ethical issues related to the pre-
scription of generic ISDs. This is particularly topical and
important given the recent presence of generic ISDs on
the market.
What are the key messages?
Generic ISDs are economical but could pose a theo-
retical risk to transplant patients. If risks are reduced by
safeguard policies and if their use is shown to be clearly
economic and safe, prescribing generic ISDs would be
ethical.
Implications for future research/policy
Our review leads us to conclude that a comprehensive
cost-effectiveness analysis of generic ISDs and clinical
studies in de novo and stable transplant patient for every
new generic ISD are necessary.
Introduction
Renal transplantation is one of the greatest medical ad-
vances of the twentieth century, improving chances of
survival and quality of life for end-stage renal disease pa-
tients. This medical success has been made possible
through immunosuppressive drugs (ISDs) that prevent
graft rejection. Patients are required to take these drugsfor the graft life span. Although ISDs decrease graft re-
jection, they are associated with multiple adverse effects.
They are also expensive: the annual cost of immunosup-
pressive treatment can be as high as C$15,000 per patient
[1]. According to the Canadian Institute for Health In-
formation, the wholesale value of Canadian purchases of
ISDs grew more quickly between 2004 and 2010 than pur-
chases in any other major therapeutic category [2]. The re-
cent arrival on the Canadian market of generic ISDs could
lower these costs. The Institut national d’excellence en
santé et en services sociaux (INESS), a provincial orga-
nization in Quebec with the mission to promote clinical
excellence and the efficient use of resources in the health
and social services sector, recently published a Notice to
the Minister, refusing to exempt the brand-name versions
of tacrolimus from Quebec’s lowest price policy [3]. How-
ever, the use of generic ISDs raises many ethical questions
regarding distributive justice, physician responsibilities,
conflict of interest and informed consent. In this paper, we
look more closely at these issues, as well as various
position statements on generic ISDs. We do not examine
situations related to specific immunosuppressive drugs.Review
Generic immunosuppressive drugs
Although generic drugs are widely accepted in the medical
community, the situation with ISDs is different, as many
of them are “critical dose drugs”. Health Canada defines
critical dose drugs as “those drugs where comparatively
small differences in dose or concentration lead to dose-
and concentration-dependent, serious therapeutic failures
and/or serious adverse drug reactions” [4]. Health Canada
recognizes only nine critical dose drugs, three of which are
commonly used ISDs: cyclosporine, tacrolimus and siroli-
mus [4]. These drugs are monitored closely by blood con-
centration dosage to achieve an optimal therapeutic effect.
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market in 1995, the majority of articles on the use of
generic ISDs have highlighted the controversial nature of
this issue. A 2005 article by Taber et al., reporting a sig-
nificantly higher incidence of acute rejection in patients
who received generic cyclosporine versus those who re-
ceived the brand-name drug, contributed to the generic
controversy [5]. Even though the authors reported sig-
nificant limitations to their research, including a higher
intra-patient variation for the generic drug group, this
study has probably influenced the way transplant profes-
sionals view generics.
A generic drug has the same active ingredient as a
brand-name drug, but the excipients can be different,
which could affect the absorption of the active ingredient
and lead to a different blood concentration. To be ap-
proved by Health Canada, a generic of a critical dose drug
has to meet strict criteria of pharmaceutical equivalence
and bioequivalence with the innovator product (90% to
112% of the area under the curve). Since blood concentra-
tion is so important for critical dose drugs, generic ISDs
and innovator products are not considered freely substi-
tutable, even when they have been demonstrated to be
bioequivalent. There is also a concern about the bioequi-
valence of different generic drugs: every generic has to be
proven to be bioequivalent to the innovator product, but
not to other generic products. There is a theoretical possi-
bility of generic “drift”, i.e., a generic at one end of the ac-
ceptable range of the area under the curve (AUC) might
not be bioequivalent to another generic at the other end
of the acceptable range [6]. The main concern about the
arrival of generic drugs on the market is the possibility
of uncontrolled substitutions (i.e., substitutions that are
made without informing the prescriber), which could lead
to under- or over-immunosuppression caused by generic
drift, both of which could lead to devastating complica-
tions. As new generics enter the market, patients could
even face successive substitutions, thus increasing fluctua-
tions in drug concentrations—a known factor in poor
long-term outcomes following kidney transplantation [7].
Certain bioequivalence studies on the kidney trans-
plant population support the safe use of generic ISDs
[8-11]. However, there are also reports of observed varia-
tions in drug concentration following drug substitution
[5,12]. Both sets of studies are small without long-term
follow-up. While the evidence is not sufficiently robust
to serve as a basis for medical decisions, these studies
have probably had a significant impact on physicians’
confidence in generic ISDs. They have bolstered the ar-
guments of detractors and have likely contributed to a
widespread reluctance to prescribe generic ISDs.
Many authors nonetheless believe that the reluctance
to use generics is based on misconceptions regarding the
approval process [13]. Even though there is a theoreticalpossibility of generic drift, a review of 2,070 bioequiva-
lence studies of all drugs approved from 1996 to 2007 by
the FDA showed that, in reality, the average difference
was comparable to the variability between two batches
of the innovator drug [14]. Some authors believe that
eventually all generic drugs will be demonstrated to be
freely substitutable, following ongoing research based on
new bioequivalence study designs [6,15].
Position statements on generic immunosuppressive drugs
The Canadian Society of Transplantation (CST) issued
recommendations in April 2012 regarding the use of
generic ISDs, following a thorough review of the available
scientific literature. The CST recommended extreme cau-
tion and estimated that the use of generic ISDs posed a
significant patient safety risk, because of the lack of safety
evidence and the absence of structural safeguards to pre-
vent uncontrolled substitutions. They asked for bioequiva-
lence to be demonstrated, not only in healthy adults, but
also in transplant recipients and in subpopulations known
to have a high variability in blood concentration [1].
The American Society of Transplantation (AST) held
a conference in 2001 to review the data and issues re-
garding the use of the generic ISDs, and published a
summary of the meeting in 2003 [16]. Participants in the
forum strongly supported efforts to offer less expensive
medications, hoping to improve compliance. Most ag-
reed that the prescription of generic ISDs de novo is safe
in low-risk transplant recipients. Some expressed con-
cerns about uncontrolled substitutions, and there was
strong support for bioequivalence studies in at-risk sub-
populations. It is worth mentioning that in the US con-
text, ISDs are reimbursed only during the first three
years post-transplant. Cessation of treatment because of
financial strain is a known cause of graft failure [17].
The European Society of Organ Transplantation (ESOT)
commissioned an Advisory Committee to formulate re-
commendations on the use of generic drugs in solid organ
transplant recipients [18]. The ESOT was satisfied with
the stricter criteria issued by the European Medicines
Agency (EMA), which match those of Health Canada. The
EMA is not opposed to the use of generic drugs that meet
the new criteria, but the agency proposes to regulate
generic substitutions of critical dose drugs in vulnerable
patient populations.
The Société francophone de transplantation also issued
recommendations after generic ISDs were introduced in
the market without consulting the medical transplant
community. They supplemented the ESOT recommenda-
tions, calling for stricter criteria for bioequivalence, pre-
scription of generic ISDs by their commercial name, and
the monitoring of patients taking generic ISDs in order to
collect clinical data [19]. Table 1 summarizes the position
statements of these different transplant societies.
Table 1 Position statements of various professional societies regarding the use of generic immunosuppressive drugs
(ISDs)
Canadian Society of Transplantation
(2012) [1]
• Insufficient literature regarding efficacy and safety.
• Close monitoring with any change.
• Not recommended in pediatric patients.
• The intended drug formulation must be explicitly stated on all prescriptions to avoid substitutions.
• Educate patients about formulations and substitutions.
• Prescriber and patient should be involved in any decision to change formulation. Mandatory
notification of the prescriber should be a legal requirement.
• Licensing requirements for critical dose drugs must be re-assessed. Bioequivalence in solid organ
transplant recipients (SOTR). Requirement for generic manufacturers to provide clinical outcome
data in SOTR.
• Transplant centres should be funded according to the increased costs associated with managing
SOTR arising from the introduction of generic immunosuppression.
American Society of Transplantation
(2003) [16]
• Supports the availability of efficacious, less expensive immunosuppressive medications and endorses
efforts to introduce generic alternatives. Medication costs may contribute to non-compliance with
prescribed medical regimens.
• FDA-approved generic immunosuppressive agents appear to provide adequate immunosuppression
to low-risk patients.
• Insufficient data to make recommendations for at-risk populations (African-Americans or pediatric).
European Society for Organ
Transplantation (2011) [18]
• Generic formulations that do not meet the stricter criteria should not be used.
• Substitution should only be initiated by the transplant physician; pharmacists or insurance providers
should refrain from forcing substitution.
• Repetitive substitution should be avoided.
• Patients should be informed about substitution and taught how to identify different formulations of
the same drug so they can alert their physician if an uncontrolled substitution is made.
• The simultaneous use of different formulations in the same patients should be avoided.
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In this section, we examine in further detail the various
ethical issues related to the use of generic ISDs in renal
transplantation.
Distributive justice
Theories of distributive justice aim to describe how a so-
ciety or group should allocate its scarce resources or pro-
ducts among individuals with competing needs or claims
[20]. Since money is a scarce resource in every healthcare
system, and individuals with different illnesses have com-
peting needs, what is the best response? There are several
theories proposing principles to help decide on how to
allocate resources. These include utilitarian, egalitarian,
libertarian and communitarian theories, and the more re-
cent capabilities and well-being theories [21]. However,
none of these theories has resulted in a consensus around
principles [21,22]. It is beyond the scope of this article to
review all of these theories. Since Canada’s health system
is based on egalitarian values, one could attempt to use
egalitarian theory to resolve the allocation problem. The
egalitarian approach would involve equal opportunities for
all patients to obtain effective treatment [22]. It would
also mean reinvesting the resources saved by the use of
generic ISDs to help the most disadvantaged patients intransplantation. Egalitarian principles would be respected
if generic ISDs produced good clinical outcomes, allowing
other patients an opportunity to be treated.
Physician duties
The situation with critical dose drugs is complex. Even
though Health Canada acknowledges the bioequivalence
of generic drugs, many physicians still believe there is
some risk involved. Previous reports of increased inci-
dence of acute rejection with generic cyclosporine partly
explain this stance [5]. Physicians who are reluctant to
prescribe generic ISDs are bound by their duty of bene-
ficence towards patients and are also the stewards of a
scarce resource (organs). For many, no degree of risk is
acceptable.
Physicians’ dual responsibilities (to their patients and
society) could be conflicting [23]. As Pellegrino writes,
the Hippocratic Oath binds physicians collectively “to
duties to other physicians and to individual patients.
Neither the Oath nor the other books of the Hippocratic
Corpus mention social obligations of broader kinds,
such as responsibility for the availability, accessibility,
and affordability of health care, or collective responsi-
bility for public health, the poor, or public policy” [24].
While some authors call for a redefinition of the
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others believe the two are irreconcilable [25,26]. In a
study by Beach and colleagues, 70% of physicians felt
that their main responsibility was toward individual pa-
tients rather than society [27]. Also, in a review of quan-
titative surveys on physicians’ attitudes toward rationing,
it has been shown that the latter are generally willing to
consider cost in clinical decisions and are in favour of
cost containment; however, when asked about cases in
which the aims and consequences of cost containment
are specified, their support decreases noticeably [28].
These findings are not surprising, given that physicians
have a personal relationship with their patients who
want to feel that their well-being comes first. Physicians
are conscious of the need for cost containment, but
would rather not see benefits withheld from their pa-
tients. Maynard states that in a public healthcare system,
prioritization is in fact determined by physicians who
provide the treatments they consider most appropriate,
not necessarily in relation to need or comparative cost-
effectiveness, as should be the case [29].
Risk-benefit analysis (RBA)
Risk-benefit analyses of the use of generic ISDs vary
from country to country. In the United States, for in-
stance, it has been documented that patients who have
to pay for brand-name ISDs bear economic burdens that
truly affect their lives; the out-of-pocket expenses for
these ISDs lead to non-compliance, graft loss and ad-
verse complications [17]. Seeing their patients’ distress,
physicians might be more likely to prescribe generic
ISDs. For Canadian patients, the economic burdens of
brand-name medication are far less onerous. Prescribing
generics would likely not significantly increase com-
pliance or decrease adverse events resulting from non-
compliance. Even if some individuals were relieved by
reduced treatment costs, the greatest advantages would
be to other patients and to the healthcare system, which
would benefit from additional available resources. These
benefits are, however, extremely difficult to quantify. It is
also very difficult to ascertain the risks, given the few
available studies in the literature [8-12,30-33]. There is a
small theoretical risk of a variation in the drug concen-
tration. Even though this risk is unquantifiable, the con-
sequences could be disastrous for both patients and
society. Under-immunosuppression could lead to graft
loss while over-immunosuppression could lead to neo-
plastic complications or life-threatening infections. From
an individual perspective, an RBA analysis may not sup-
port the use of generic ISDs in Canada, since individuals
derive no obvious benefits and may incur some risk. From
a wider societal perspective, however, an RBA analysis
might show benefits to be obtained through potential
cost savings.In the UK, the National Health Service is seeking ways
to reinvest efficiency savings into clinical services in
order to improve the quality of patient care [34]. These
strategies have led some transplant centres to use gen-
eric tacrolimus and generic mycophenolate mofetil in
both de novo and stable renal transplanted patients [34].
While this paper is focused on renal transplantation,
the same questions have been raised in thoracic trans-
plantation as well [35]. The risk acceptability may be
lower in thoracic transplantation, as there is no alter-
native treatment like dialysis. Using the precautionary
principle, substitution could be started in renal trans-
plantation and extended to thoracic and other life-saving
organ transplantation if post-approval clinical data of the
generic ISDs showed solid clinical equivalence.
Conflict of interest
The use of generic drugs also raises the issue of conflict of
interest. Pharmaceutical companies are omnipresent in the
medical community, and manufacturers of brand-name
ISDs are also very active in the transplantation world.
These companies offer grants and speaker honoraria; they
are trusted, as they have been in the business for a while
and have invested in long-term relationships with physi-
cians. They also sponsor professional organizations in the
field of transplantation. It has been documented that even
though 61% of physicians believe their decisions are not
influenced by drug companies’ marketing strategies,
only 16% have the same confidence in their colleagues
[36]. A review of the literature on conflict of interest
and drug companies showed that physician-industry in-
teractions do affect professional behaviour and prescrib-
ing [37]. The review also showed that these interactions
reduce the prescription of generic drugs. It is also worth
mentioning that some scientific papers that promote
the use of generic ISDs are sponsored by generic drug
companies [8]. It is important to take these conflicts of
interest into account in the debate around the use of
generic ISDs.
Patients’ informed consent
Many campaigns aim to promote the use of generic
drugs or to reassure the population when substitution is
mandatory, as is the case under the public prescription
drug insurance plans of many provinces and most pri-
vate insurance plans in Canada [38]. The market share
of generic drugs in this country has been increasing over
the last decade, reaching 63% in 2012 [39], partly be-
cause of changes in government and insurance pro-
grams, but also because of public confidence. When
prescribing a generic ISD, physicians must inform their
patients that the drug in question may be different from
other generic drugs. Efforts are needed to educate pa-
tients about the possible effects of substitution. Patients
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medication in order to detect and report any substi-
tution. This education is necessary to obtain patients’ in-
formed consent. If the information is not presented in a
nuanced manner, it could potentially undermine much-
needed public trust in the generic approval process.
Should well-informed patients refuse to take generic
ISDs, their autonomy would be respected. However, under
most insurance plans, they would have to cover the cost
difference between the generic and brand-name drug.
Some might argue that the opportunity for patients to ex-
ercise their autonomy depends on their income, as many
would not be able to afford the brand-name drug. But this
could be argued for any generic drug as well, and if we
were to rank autonomy higher than societal health by
covering the cost of preferred versions of the drug, there
would be a greater loss in health coverage, since generic
drugs save billions of dollars annually. Such a decision
would also run counter to values enshrined in the Canada
Health Act such as universality and accessibility. The
mandatory substitution policy is in accordance with
Daniels’ theory of fair equality of opportunity [22] in that
it provides an opportunity for all to access treatment while
allowing them the liberty to purchase a brand-name drug.
Logistical and economic issues
Unless it is eventually demonstrated that every generic
ISD is freely substitutable, there is a need for regulations
that would minimize the risks of uncontrolled substitu-
tions. In Canada, as in most developed countries, pharma-
cists may automatically substitute a medication without
necessarily notifying the physician [35]. Physicians may
write “no substitution” on the prescription; however,
depending on the insurance plan, the patient could be
responsible for the cost difference between the two
brands. Physicians, pharmacists and regulators would
have to work together to set new rules around generic
substitutions, and then educate their respective profes-
sional communities.
While generic ISDs are invariably cheaper than brand-
name drugs, their use is not necessarily economical.
Since all professional associations recommend close mo-
nitoring of any substitutions [1,16,18,40], the costs of in-
creased monitoring for both medical staff and patients
(time, lost wages, travel to hospital) must be evaluated.
It is worth noting that increased monitoring would
probably only be necessary in the short term, and costs
would be lowered once the substitution was proven to
be safe and effective. Substitution could therefore prove
to be an economical choice in the long term. There is
also a consensus around the need for increased patient
education, which comes at a cost. The CST has openly
asked for funds to be allocated to transplant centres to
meet these new needs [1]. As stated earlier, there wouldbe costs associated with implementing new regulations
and providing information to physicians and pharma-
cists. A comprehensive cost-benefit analysis including
these new costs is needed to assess the cost-effectiveness
of generic ISDs.
The use of generic ISDs may also involve logistical is-
sues around drug shortages. In Canada, most provinces
have policies to regulate generic prices. Although these
price cap policies may be economical in the short term,
they may also have been a factor in recent drug short-
ages [41]. As the prices are lowered, it becomes less
profitable to manufacture the drugs and a shortage of
generic ISDs could be disastrous.
Conclusion
To determine whether it is ethical to prescribe generic
ISDs, we recommend a comprehensive cost-effectiveness
analysis to ascertain the benefits, as well as clinical studies
in de novo and stable renal transplant patients for every
generic ISD. We recommend minimizing the risks that
could be associated with generic drift by implementing
new policies such as a law prohibiting non-physicians
(pharmacists, insurance providers, etc.) from authorizing
substitutions of brand-name ISDs with generic ISDs, or
substitutions between generic ISDs. If generic ISDs are
demonstrated to be clinically safe and more cost-effective
than brand-name drugs, and if policies are implemented
to minimize the risks, it would be ethical to use them,
since the benefits to society would be greater than the
risks to individual patients.
Competing interests
Julie Allard has no competing interests.
Marie-Chantal Fortin has no competing interests.
Authors’ contributions
JA and M-CF were both involved in the literature review and the writing of
the article. Both authors have read and approved the final manuscript.
Acknowledgements
Dr. Fortin holds a KRESCENT New Investigator award and is an FRSQ
research scholar.
Author details
1Centre de recherche du Centre hospitalier de l′Université de Montréal
(CRCHUM), 900 Saint-Denis Street, Montreal, Quebec H2X 0A9, Canada.
2Nephrology and Transplantation Division, Centre hospitalier de l’Université
de Montréal (CHUM), 1560 Sherbrooke Street East, Montreal, Quebec H2L
4 M1, Canada. 3Department of Social and Preventive Medicine, Bioethics
Program, School of Public Health, Université de Montréal, Montreal, Canada.
Received: 29 May 2014 Accepted: 11 August 2014
Published: 9 September 2014
References
1. Harrison JJ, Schiff JR, Coursol CJ, Daley CJ, Dipchand AI, Heywood NM,
Keough-Ryan TM, Keown PA, Levy GA, Lien DC, Wichart JR, Cantarovich M:
Generic immunosuppression in solid organ transplantation: a Canadian
perspective. Transplantation 2012, 93:657–665.
2. Canadian Institute of Health Information: Drivers of Prescription Drugs
Spending in Canada. Ottawa, Ontario: CIHI; 2012.
Allard and Fortin Canadian Journal of Kidney Health and Disease 2014, 1:23 Page 7 of 7
http://www.cjkhd.org/content/1/1/233. Institut national d’excellence en santé et en services sociaux: Avis au Ministre.
Québec: INESS; 2014. Available from : https://www.inesss.qc.ca/fileadmin/doc/
INESSS/Inscription_medicaments/Avis_au_ministre/Juin_
2014/_AvisMinistre_WEB_innovateurs_2014_06.pdf (in French only).
4. Health Canada Guidance Document: Comparative bioavailability standards:
formulations used for systemic effects. [cited 2014 April 23rd]. Ottawa: Health
Canada; 2012. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/
applic-demande/guide-ld/bio/gd_standards_ld_normes-eng.php#a2.1.1.6.
5. Taber DJ, Baillie GM, Ashcraft EE, Rogers J, Lin A, Afzal F, Baliga P,
Rajagopalan PR, Chavin KD: Does bioequivalence between modified
cyclosporine formulations translate into equal outcomes? Transplantation
2005, 80:1633–1635.
6. Lionberger R, Jiang W, Huang SM, Geba G: Confidence in generic drug
substitution. Clin Pharmacol Ther 2013, 94:438–440.
7. Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T: High
within-patient variability in the clearance of tacrolimus is a risk factor for
poor long-term outcome after kidney transplantation. Nephrol Dial
Transplant 2010, 8:2757–2763.
8. Alloway RR, Sadaka B, Trofe-Clark J, Wiland A, Bloom RD: A randomized
pharmacokinetic study of generic tacrolimus versus reference tacrolimus
in kidney transplant recipients. Am J Transplant 2012, 12:2825–2831.
9. Bloom RD, Trofe-Clark J, Wiland A, Alloway RR: A randomized, crossover
pharmacokinetic study comparing generic tacrolimus vs. the reference
formulation in subpopulations of kidney transplant patients. Clin Transplant
2013, 6:E685–E693.
10. Khatami SM, Taheri S, Azmandian J, Sagheb MM, Nazemian F, Razeghi E,
Shahidi S, Sadri F, Shamshiri AR, Sayyah M: One-year multicenter
double-blind randomized clinical trial on the efficacy and safety
of generic cyclosporine (iminoral) in De novo kidney transplant
recipients. Exp Clin Transplant 2013, published ahead of print.
doi:10.6002/ect.2013.0139.
11. Danguilan RA, Lamban AB, Luna CA, Bacinillo M, Momongan MI: Pilot study
on the efficacy and safety of generic mycophenolate mofetil (mycept)
compared with cellcept among incident low-risk primary kidney trans-
plant recipients. Transplant Proc 2014, 2:415–417.
12. Momper JD, Ridenour TA, Schonder KS, Shapiro R, Humar A,
Venkataramanan R: The impact of conversion from prograf to generic
tacrolimus in liver and kidney transplant recipients with stable graft
function. Am J Transplant 2011, 11:1861–1867.
13. Christians U, Klawitter J, Clavijo CF: Bioequivalence testing of
immunosuppressants: concepts and misconceptions. Kidney Int Suppl
2010, 77:S1–S7.
14. Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, Yang Y,
Yu LX, Woodcock J: Comparing generic and innovator drugs: a review of
12 years of bioequivalence data from the United States Food and Drug
Administration. Ann Pharmacother 2009, 43:1583–1597.
15. Yu Y, Teerenstra S, Vanmolkot F, Neef C, Burger D, Maliepaard M:
Interchangeability of gabapentin generic formulations in the
Netherlands: a comparative bioavailability study. Clin Pharmacol Ther
2013, 94:519–524.
16. Alloway RR, Isaacs R, Lake K, Hoyer P, First R, Helderman H, Bunnapradist S,
Leichtman A, Bennett MW, Tejani A, Takemoto SK: Report of the american
society of transplantation conference on immunosuppressive drugs and
the Use of generic immunosuppressants. Am J Transplant 2003, 3:1211–1215.
17. Gordon EJ, Prohaska TR, Sehgal AR:
The financial impact of immunosuppressant expenses on new kidney
transplant recipients. Clin Transplant 2008, 22:738–748.
18. van Gelder T: European Society for Organ Transplantation Advisory
Committee recommendations on generic substitution of
immunosuppressive drugs. Transpl Int 2011, 24:1135–1141.
19. Le Meur Y, Sebbag L, Anglicheau D, Kama N, Billaud E, Hulin A, Marquet P:
Recommandation de la Société francophone de transplantatelon
sur l′utilisation des génériques des immunosuppresseurs. Le Courrier de la
Transplant 2012, 12:102–106.
20. Roemer JE: Theories of Distributive Justice. Cambridge, Mass: Harvard
University Press; 1998.
21. Beauchamp TL, Childress JF: Principles of Biomedical Ethics. New York, NY:
Oxford University Press; 2001.
22. Daniels N: Justice, health, and healthcare. Am J Bioeth 2001, 2:2–16.
23. Minogue B: The two fundamental duties of the physician. Acad Med 2000,
75:431–442.24. Pellegrino ED: The medical profession as a moral community. Bull N Y
Acad Med 1990, 3:221–232.
25. Kassirer JP: Our endangered integrity — It Can only Get worse. New Engl
J Med 1997, 23:1666–1667.
26. Dyer AR: Patients, not costs, come first: should doctors cut costs at the
bedside? Hastings Cent Rep 1986, 16:5–7.
27. Beach MC, Meredith LS, Halpern J, Wells KB, Ford DE: Physician
conceptions of responsibility to individual patients and distributive
justice in health care. Ann Fam Med 2005, 3:53–59.
28. Strech D, Persad G, Marckmann G, Danis M: Are physicians willing to ration
health care? Conflicting findings in a systematic review of survey
research. Health Policy 2009, 2–3:113–124.
29. Maynard A: Health care rationing: doing it better in public and private
health care systems. J Health Polit Policy Law 2013, 38:1103–1127.
30. Cattaneo D, Perico N, Remuzzi G: Generic cyclosporine formulations: more
open questions than answers. Transpl Int 2005, 4:371–378.
31. Min SI, Ha J, Kim YS, Ahn SH, Park T, Park DD, Kim SM, Min SK, Hong H,
Ahn C, Kim SJ: Therapeutic equivalence and pharmacokinetics of generic
tacrolimus formulation in de novo kidney transplant patients.
Nephrol Dial Transplant 2013, 12:3110–3119.
32. Pamugas GE, Danguilan RA, Lamban AB, Mangati VB, Ona ET: Safety and
efficacy of generic cyclosporine arpimune in Filipino low-risk primary
kidney transplant recipients. Transplant Proc 2012, 1:101–108.
33. Spence MM, Nguyen LM, Hui RL, Chan J: Evaluation of clinical and safety
outcomes associated with conversion from brand-name to generic
tacrolimus in transplant recipients enrolled in an integrated health care
system. Pharmacotherapy 2012, 11:981–987.
34. Devaney A, Lee M: The use of generic immunosuppression for transplant
patients: a UK perspective. Eur J Hosp Pharm 2013, 20:272–274.
35. Uber PA, Ross HJ, Zuckermann AO, Sweet SC, Corris PA, McNeil K, Mehra MR:
Generic Drug Immunosuppression in Thoracic Transplantation:
An ISHLT Educational Advisory. J Heart Lung Transplant 2009, 7:655–660.
36. Blumenthal D: Doctors and Drug Companies. New Engl J Med 2004,
18:1885–1890.
37. Wazana A: Physicians and the pharmaceutical industry: is a gift ever just
a gift? JAMA 2000, 3:373–380.
38. Lynas K: Private insurers implementing policies making generic
substitution mandatory. Can Pharm J Revue des Pharmaciens du Canada
2012, 6:245.
39. The Canadian Generic Pharmaceutical Association: The Canadian Generic
Market Year 2012. Montreal: Association TCGP; 2013. [cited 2014 April
23rd]. Available from: http://www.canadiangenerics.ca/fr/resources/
market_trends.asp.
40. Sabatini S, Ferguson RM, Helderman JH, Hull AR, Kirkpatrick BS, Barr WH:
Drug substitution in transplantation: A National Kidney Foundation
white paper. Am J Kidney Dis 1999, 2:389–397.
41. Labrie Y: How can we Prevent Drug Shortage. Montréal: Montreal Economic
Institute; 2012.
doi:10.1186/s40697-014-0023-8
Cite this article as: Allard and Fortin: Is it ethical to prescribe generic
immunosuppressive drugs to renal transplant patients? Canadian Journal of
Kidney Health and Disease 2014 1:23.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
